Etripamil

Names

[ Name ]:
Etripamil

[Synonym ]:
MSP-2017
UNII:S82A18Y42P
(-)-MSP-2017
Methyl 3-(2-{[(4S)-4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl](methyl)amino}ethyl)benzoate
Benzoic acid, 3-[2-[[(4S)-4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl]methylamino]ethyl]-, methyl ester
Etripamil

Biological Activity

[Description]:

Etripamil (MSP-2017) is a short-acting L-type calcium-channel antagonist with a rapid onset of action designed for intranasal administration, used to treat Paroxysmal Supraventricular Tachycardia (PSVT). Etripamil (MSP-2017) slows atrioventricular nodal conduction and prolongs atrioventricular nodal refractory periods by inhibiting calcium ion influx through the calcium slow channels in the atrioventricular node cells[1][2].

[Related Catalog]:

Signaling Pathways >> Membrane Transporter/Ion Channel >> Calcium Channel

Research Areas >> Cardiovascular Disease

[Target]

L-type calcium channel

[References]

[1]. Stambler BS, et al. Etripamil Nasal Spray for Rapid Conversion of Supraventricular Tachycardia to Sinus Rhythm. J Am Coll Cardiol. 2018 Jul 31;72(5):489-497.

[2]. Milestone Pharmaceuticals Announces USAN Approval of Generic Name “Etripamil” for its Phase 2 Clinical Development Product for the Treatment of Paroxysmal Supraventricular Tachycardia.

Chemical & Physical Properties

[ Density]:
1.1±0.1 g/cm3

[ Boiling Point ]:
593.8±50.0 °C at 760 mmHg

[ Molecular Formula ]:
C₂₇H₃₆N₂O₄

[ Molecular Weight ]:
452.59

[ Flash Point ]:
312.9±30.1 °C

[ Exact Mass ]:
452.267517

[ LogP ]:
4.14

[ Vapour Pressure ]:
0.0±1.7 mmHg at 25°C

[ Index of Refraction ]:
1.534

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.